On April 21, 2026 Tubulis reported that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting, being held May 29 – June 2, 2026, in Chicago. The presentation by Prof. Dr. Toon Van Gorp, clinical investigator of the study, will provide an update of maturing data from the ongoing dose escalation part of the ovarian cancer cohort.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the oral presentation:
Title: NAPISTAR 1-01: Results of phase 1 dose escalation of monotherapy with TUB-040, a novel NaPi2b-targeting exatecan ADC, in patients (pts) with platinum-resistant ovarian cancer (PROC)
Presenter: Dr. Toon Van Gorp, Professor of Gynaecological Oncology at the University of Leuven, Belgium
Session Category and Title: Rapid Oral Abstract Session: Gynecologic Cancer
Session Date and Time: May 30, 2026; 08:00 – 09:30 AM CDT
Location: McCormic Place, E450a
Abstract Number: 5513
About TUB-040 and the Tubutecan Technology
Tubulis’ lead antibody-drug conjugate (ADC) TUB-040 is directed against NaPi2b, an antigen highly overexpressed in ovarian cancer, lung adenocarcinoma, and endometrial cancer. It consists of an IgG1 antibody targeting NaPi2b equipped with Tubulis’ proprietary Tubutecan technology, connecting the Topoisomerase I inhibitor, exatecan, through a cleavable linker system based on the company’s proprietary P5 conjugation technology with a homogeneous DAR of 8. Based on novel chemistry for cysteine-selective conjugation, the technology enables the development of stable, highly targeted ADCs optimized for the on-target delivery of the topoisomerase-1 inhibitor while minimizing systemic toxicity. The candidate has already demonstrated robust clinical activity with a favorable safety profile as monotherapy in patients with platinum-resistant high-grade ovarian cancer (PROC), reported at ESMO (Free ESMO Whitepaper) 2025. It is currently being further investigated in a multicenter Phase I/IIa study (NAPISTAR1-01, NCT06303505) in PROC and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
(Press release, Tubulis, APR 21, 2026, View Source [SID1234664645])